ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended

ImmuCell Announces Unaudited Financial Results

the Quarter Ended June 30, 2025

PORTLAND, Maine - August 14, 2025 - ImmuCell

Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops,

manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle,

today announced its unaudited financial results for the quarter ended June 30, 2025.

Product Sales Highlights:

Preliminary, unaudited product sales for the second quarter of 2025

were first reported on July 9, 2025. There are no changes to those figures.

Management's Discussion:

"We effectively eliminated the backlog of orders as of June 30,

2025," commented Michael F. Brigham, President and CEO of ImmuCell. "We have re-filled distributors with the inventory that

they would like to hold as we enter the third quarter when sales are generally lower. We are now building inventory to meet customer demand

going into the peak selling season towards the end of the year and into the first quarter of 2026."

"We improved our gross margin as a percentage of sales to 44%

and 43% during the three-month and six-month periods ended June 30, 2025, respectively," added Timothy C. Fiori, Chief Financial

Officer of ImmuCell. "This gross margin improvement helped us generate net income of approximately $502,000 and $1.9 million during

the three-month and six-month periods ended June 30, 2025, respectively, in contrast to significant net losses during the comparable periods

ended June 30, 2024."

"With regards to Re-Tain , we have initiated

Investigational Product use to collect market feedback about product performance in the field over the second half of 2025 and into the

first quarter of 2026," concluded Mr. Brigham. "At the same time, we are reducing product development expenses and exploring

potential strategic options for the product opportunity."

Certain Other Financial Results:

Balance Sheet Data as of June 30, 2025:

Cautionary Note Regarding Forward-Looking Statements (Safe Harbor

This Press Release and the statements to be made

in the related conference call referenced herein contains "forward-looking statements" within the meaning of the Private Securities

Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to

historical or current facts and will often include words such as "expects", "may", "anticipates",

"aims", "intends", "would", "could", "should", "will", "plans",

"believes", "estimates", "targets", "projects", "forecasts", "seeks"

and similar words and expressions. Such statements include, but are not limited to, any forward-looking statements relating to: our plans,

goals and strategies for our business; projections of future financial or operational performance; the timing and outcome of pending or

anticipated applications for regulatory approvals and pending or anticipated regulatory inspections of our facilities and those of our

contract manufacturers; future demand for our products; future adoption of Re-Tain by dairy producers; growth in

acceptance of our First Defense product line by dairy and beef producers; the impact of international disputes

(including Russia's invasion of Ukraine and unrest in the Middle East) on the world economy including inflation and the price and

availability of grain and oil; the impact of the global supply-chain disruptions on our ability to obtain, in a timely and cost-effective

fashion, all the supplies and components we need to produce our products; the impact of inflation, tariffs and rising interest rates on

our operating expenses and financial results; the scope and timing of ongoing and future product development work and commercialization

of our products; future costs of product development efforts; future incidence rates of subclinical mastitis and producers' level

of interest in treating subclinical mastitis; the expected efficacy of new products; estimates about the market size for our products;

future market share of and revenue generated by current products and products still in development; our ability to increase production

output and reduce costs of goods sold per unit; the adequacy of our own manufacturing facilities or those of third parties with which

we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships;

the efficacy of our contamination remediation efforts; whether or not we will experience future contamination events; the anticipated

costs of (or time to complete) planned expansions of our manufacturing facilities and the adequacy of our funds available for these projects;

the robustness of our manufacturing processes to meet future demand and related technical issues; estimates about our future production

capacity, efficiency and yield; the salability of products currently held in inventory pending regulatory approval; future regulatory

requirements relating to our products; future expense ratios and margins; the future consequences and effectiveness of our investments

in our business; future compliance with, or waivers of, bank debt covenants; anticipated changes in our manufacturing capabilities and

efficiencies; our future effectiveness in competing against competitors within both our existing and our anticipated product markets;

projections about depreciation expense and its impact on income for book and tax return purposes; and any other statements that are not

historical facts. These statements are intended to provide management's current expectation of future events as of the date of this earnings

release, are based on management's estimates, projections, beliefs and assumptions as of the date hereof; and are not guarantees of future

performance. Such statements involve known and unknown risks and uncertainties that may cause the Company's actual results, financial

or operational performance or achievements to be materially different from those expressed or implied by these forward-looking statements,

including, but not limited to, those risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval,

production and marketing of our products (including the First Defense product line and Re-Tain ),

competition within our anticipated product markets, customer acceptance of our new and existing products, product performance, alignment

between our manufacturing resources and product demand (including the consequences of backlogs), uncertainty associated with the timing

and volume of customer orders as we come out of a prolonged backlog, adverse impacts of supply chain disruptions on our operations and

customer and supplier relationships, commercial and operational risks relating to our current and planned expansion of production capacity,

and other risks and uncertainties detailed from time to time in filings we make with the SEC, including our Quarterly Reports on Form

10-Q, our Annual Reports on Form 10-K and our Current Reports on Form 8-K. Such statements involve risks and uncertainties and are based

on our current expectations, but actual results may differ materially due to various factors. In addition, there can be no assurance that

future risks, uncertainties or developments affecting us will be those that we anticipate. We undertake no obligation to update any forward-looking

statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or

Condensed Statements of Operations (Unaudited)

Selected Balance Sheet Data (In thousands)

Non-GAAP Financial Measures:

Generally, a non-GAAP financial measure is a numerical measure of a

company's performance, financial position or cash flow that either excludes or includes amounts that are not normally included in

or excluded from the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included

in this press release should be considered in addition to, and not as a substitute for or superior to, the comparable measure prepared

in accordance with GAAP. We believe that considering the non-GAAP measure of Earnings Before Interest, Taxes, Depreciation and Amortization

(EBITDA) assists management and investors by looking at our performance across reporting periods on a consistent basis excluding certain

charges from our reported net income (loss). Adjusted EBITDA is calculated and reconciled to the most comparable GAAP financial measure

in the following table:

Cash payments to satisfy debt repayment obligations and to make capital

expenditure investments are other uses of cash that are not included in the calculation of EBITDA, which management also considers when

assessing its cash flows.

The Company is planning to host a conference call on Friday, August 15, 2025 at 9:00 AM ET to discuss the unaudited financial results

for the quarter ended June 30, 2025. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412)

317-5499 (international). A teleconference replay of the call will be available until August 22, 2025 at (877) 344-7529 (toll free) or

(412) 317-0088 (international), utilizing replay access code #5659118. Investors are encouraged to review the Company's updated

Corporate Presentation slide deck that provides an overview of the Company's business and is available under the "Investors"

tab of the Company's website at www.immucell.com, or by request to the Company. An updated version of the slide deck was made available

after the market closed on Thursday, August 14, 2025.

ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically

proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets

First Defense , which provides Immediate Immunity to newborn dairy and beef calves, and is developing

Re-Tain , a novel treatment for subclinical mastitis in dairy cows without FDA-required milk discard or pre-slaughter

withdrawal label restrictions that provides an alternative to traditional mastitis antibiotics. Press releases and other information about

the Company are available at: http://www.immucell.com.